HopeStage
Back to all studies
CompletedNCT00640601

Long-term quetiapine XR for clinical improvement in schizophrenia

About this titleRead the official source — NCT00640601
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Garran and 35 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2008
Recruitment status
Completed
Enrollment listed in the registry
331
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Australia, Canada, China, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00640601
Official title
Show the full official title

A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garran, Australia · Newcastle, Australia · Brisbane, Australia

34 more locations
  • Meadowbrook, Australia
  • Dandenong, Australia
  • Calgary, Canada
  • Claresholm, Canada
  • Red Deer, Canada
  • Vancouver, Canada
  • Victoria, Canada
  • Miramichi, Canada
  • St. John's, Canada
  • Sydney, Canada
  • Belleville, Canada
  • Brantford, Canada
  • Chatham, Canada
  • Cornwall, Canada
  • Greater Sudbury, Canada
  • London, Canada
  • Markham, Canada
  • Mississauga, Canada
  • Newmarket, Canada
  • Oakville, Canada
  • Orléans, Canada
  • Toronto, Canada
  • Windsor, Canada
  • Gatineau, Canada
  • Greenfield Park, Canada
  • Montreal, Canada
  • Québec, Canada
  • Rouyn-Noranda, Canada
  • Verdun, Canada
  • Prince Albert, Canada
  • Saskatoon, Canada
  • Hong Kong, Hong Kong
  • Seoul, South Korea
  • China

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine Fumarate Extended- Release.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies